Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer

PDF  |  How to cite

Oncotarget. 2021; 12:2232-2233. https://doi.org/10.18632/oncotarget.28096

Metrics: PDF 942 views  |   ?  

Takahito Sugase1,2,3, Tsuyoshi Takahashi1, Satoshi Serada2, Minoru Fujimoto2, Tomoharu Ohkawara2, Kosuke Hiramatsu2, Masahiro Koh1, Yurina Saito1, Koji Tanaka1, Yasuhiro Miyazaki1, Tomoki Makino1, Yukinori Kurokawa1, Makoto Yamasaki1, Kiyokazu Nakajima1, Kazuhiro Hanazaki3, Masaki Mori1, Yuichiro Doki1 and Tetsuji Naka2

1 Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan
2 Center for Intractable Immune Disease, Kochi University, Nankoku, Japan
3 Department of Surgery, Kochi University, Nankoku, Japan

Published: Ocotober 12, 2021

Copyright: © 2021 Sugase et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 1C, the image in row 2, column 2 is an accidental duplicate of the image in row 2, column 4. The corrected Figure 1C, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:32917–32928. DOI: https://doi.org/10.18632/oncotarget.25952

Figure 1: Immunohistochemical (IHC) staining for lipolysis-stimulated lipoprotein receptor (LSR) in gastric cancer (GC) patient samples. (C) Primary GC, lymph node metastasis, and distant metastasis (peritoneum and liver) of 7 patients with GC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28096